| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | quizartinib | CTRPv2 | pan-cancer | AAC | 0.057 | 0.1 |
| mRNA | ruxolitinib | GDSC1000 | pan-cancer | AAC | -0.05 | 0.1 |
| mRNA | SID 26681509 | CTRPv2 | pan-cancer | AAC | 0.057 | 0.1 |
| mRNA | pac-1 | GDSC1000 | pan-cancer | AAC | -0.053 | 0.1 |
| mRNA | BRD-K03911514 | CTRPv2 | pan-cancer | AAC | -0.077 | 0.1 |
| mRNA | rigosertib | CTRPv2 | pan-cancer | AAC | 0.049 | 0.1 |
| mRNA | pifithrin-mu | CTRPv2 | pan-cancer | AAC | -0.051 | 0.1 |
| mRNA | BRD-K27188169:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.075 | 0.1 |
| mRNA | PD-0325901 | gCSI | pan-cancer | AAC | 0.077 | 0.1 |
| mRNA | Erlotinib | gCSI | pan-cancer | AAC | -0.085 | 0.1 |